Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 21844498)

1.

Androgen deprivation therapy and cardiovascular risk.

Punnen S, Cooperberg MR, Sadetsky N, Carroll PR.

J Clin Oncol. 2011 Sep 10;29(26):3510-6. doi: 10.1200/JCO.2011.35.1494. Epub 2011 Aug 15.

2.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

3.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

4.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

5.

Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.

Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K.

J Clin Oncol. 2015 Mar 1;33(7):716-22. doi: 10.1200/JCO.2014.57.2743. Epub 2015 Jan 5.

PMID:
25559808
6.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
7.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

8.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

9.

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6. doi: 10.1016/j.ijrobp.2011.04.067. Epub 2011 Jun 25.

PMID:
21708431
10.

Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.

Holmes L Jr, Chan W, Jiang Z, Du XL.

Prostate Cancer Prostatic Dis. 2007;10(4):388-95. Epub 2007 May 8.

PMID:
17486111
11.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

12.

Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?

Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA.

Eur J Cancer. 2012 Jul;48(11):1664-71. doi: 10.1016/j.ejca.2012.01.026. Epub 2012 Feb 13.

PMID:
22336663
13.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

14.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

15.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
16.

Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi: 10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14.

PMID:
22981709
17.

Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.

Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, Jenkins T, Hamilton EJ, Bate K, Chan I, Zajac JD, Grossmann M.

Andrology. 2013 Jul;1(4):583-9. doi: 10.1111/j.2047-2927.2013.00093.x. Epub 2013 May 20.

PMID:
23686896
18.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

19.

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7.

PMID:
21645976
20.

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.

BJU Int. 2009 Nov;104(9):1208-14. doi: 10.1111/j.1464-410X.2009.08593.x. Epub 2009 Apr 17.

PMID:
19388987
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk